Fox Chase Cancer Center Board Elects David G. Marshall Chairman
Louis Della Penna to assume Marshall's current office of vice chairman
David G. Marshall
PHILADELPHIA (Nov. 6, 2008) — Fox Chase Cancer Center's board of directors has elected David G. Marshall to succeed William J. Avery as board chairman on February 26 at the first meeting of the board in 2009. The election took place Oct. 30 at the board's fall meeting.
Marshall, who lives in New Hope, Pa., has been a member of the Fox Chase board since 1994. He became one of four new vice chairmen in March 2008.
The board elected Louis Della Penna Sr., CFP, another board member from New Hope, to become a vice chairman in February, replacing Marshall in that role as he assumes the chairmanship. Della Penna will also assume the chairmanship of the institutional advancement committee of the board, which oversees Fox Chase's philanthropic efforts.
Avery, a resident of Gwynedd Valley, Pa., has served as board chairman since 2003.
"After the able, confident leadership we've enjoyed from Bill Avery, we are fortunate to have another talented leader step forward at this time of great opportunity for Fox Chase Cancer Center," said Michael V. Seiden, M.D., Ph.D., president and chief executive officer of Fox Chase. "David Marshall has the optimism, strength, and vision to help Fox Chase expand in the coming years to build on its national leadership position in cancer research, prevention, and treatment. I look forward to our enhanced partnership. He will be a terrific chair."
"Cancer has had a profound impact on my family," said Marshall. "My mother and all five of her sisters died of cancer. Three of my cousins have also died of cancer. I know that I am not in a position to find the cure for cancer, but I am determined to do whatever I can to help Fox Chase Cancer Center do so.
"Fox Chase has a spectacular history, being the nation's first cancer hospital, the first with two Nobel Prize winners, and one of the nation's first comprehensive cancer centers, as well as the first to have a cancer prevention center to go along with its fabulous research and treatment facilities. It is incumbent upon the board, the researchers, the doctors, and the entire staff to assure that Fox Chase's future is every bit as illustrious as its past. The work being done by the researchers and clinicians at Fox Chase could hardly be more important."
Marshall is chairman and CEO of Amerimar Realty Company. Created by Marshall in 1987, Amerimar has commercial and residential holdings throughout the country. The company is known for its successful development of The Rittenhouse, which includes condominiums and hotel and restaurant facilities at 210 West Rittenhouse Square in Center City.
Marshall currently chairs the Fox Chase board's building and grounds committee. He also serves on the executive committee, the regional development and ventures committee, and the finance committee, for which he is chair of the investment subcommittee.
In addition to his work with Fox Chase, Marshall serves as a director of the Damon Runyon Cancer Research Fund and is a member of its executive committee. He is also president of the Central Philadelphia Development Corporation and was vice chair of the Federation Allied Jewish Appeal. He serves as a director for the Center City District, SEI Center for Advanced Studies in Management, Friends of Rittenhouse Square, and the Foreign Policy Research Institute. For the University of Pennsylvania's Wharton School, Marshall chairs the research committee and serves on the executive committee of the Real Estate Center. Formerly, he was a director of the Wharton School's undergraduate executive board.
Fox Chase's newest vice chairman, Lou Della Penna, began his term as a board member in 2007. He serves on both the institutional advancement and the building and grounds committees—assignments where he has a key role in shaping fundraising strategies and helping guide Fox Chase expansion plans. Della Penna has also served on the executive committee for Fox Chase Cancer Center's ongoing capital campaign since 2005.
Della Penna is founder and former chairman of LDP Consulting Group, Inc., a New Jersey-based employee-benefits consulting company. Since 1972, LDP Consulting has worked with boards of education, municipalities, small businesses, and corporations to help them provide their employees with the best possible benefits at the lowest possible cost.
Della Penna has had firsthand experience as a Fox Chase patient and cancer survivor. He has noted that "from a humanitarian standpoint, it's so important to support cancer research. Sooner or later, everyone will be touched by this disease in some way."
Della Penna is a thought leader on topics related to health-care cost containment, managed-care alternatives, and the negotiation of health-care benefits. In addition, he is a trustee for the James A. Michener Art Museum, a trustee and past chair for New Jersey's Monmouth-Ocean Foundation for Educational Enhancement, and a member and former vice chair of the advisory board for the Salvation Army of Greater Philadelphia.
Outgoing board chairman Avery is the retired chairman and CEO of Crown Cork & Seal Company, Inc. He will remain on the Fox Chase board and is a member of the boards of Lincoln National Corporation, Rohm & Haas, The Franklin Institute, Gwynedd Mercy College, Historic Philadelphia, Inc., Philadelphia Shipyard Development Corp, and the Police Athletic League (PAL) of Philadelphia.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).